Novo Holdings Portfolio Company Syndesi Therapeutics acquired by AbbVie· Deal value of US$ 1 billion with US$ 130 million upfront· Novo Holdings co-created Syndesi Therapeutics in partnership with UCB Pharma and co-led the Series A financing&m.
/PRNewswire/ Novo Holdings, a leading international life sciences investor, today announces that its portfolio company Syndesi Therapeutics ( Syndesi ) has.